Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study Mark O’LoughlinXavier AndreuGrace Callagy Editorial Open access 17 May 2018 Pages: 1 - 9
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG) Jame AbrahamRobert ColemanThe Breast Cancer Therapy Expert Group (BCTEG) Review Open access 04 May 2018 Pages: 11 - 20
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer M. L. TelliD. G. StoverE. P. Winer Review Open access 07 May 2018 Pages: 21 - 31
Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients Ryo TsunashimaYasuto NaoiShinzaburo Noguchi Preclinical study 04 May 2018 Pages: 33 - 41
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway Hisako OnoYoshihiro SowaToshiyuki Sakai Preclinical study Open access 11 May 2018 Pages: 43 - 52
Genetic dissection of the BRCA2 promoter and transcriptional impact of DNA variants Eugenia Fraile-BethencourtAlberto Valenzuela-PalomoEladio A. Velasco Preclinical study 15 May 2018 Pages: 53 - 63
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer Erik J. BlokCharla C. EngelsPeter J. K. Kuppen Preclinical study Open access 15 May 2018 Pages: 65 - 74
Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE) Timothy J. WilliamsonSusan M. LoveAnnette L. Stanton Preclinical study 16 May 2018 Pages: 75 - 84
BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients Marius WunderlePaul GassAlexander Hein Clinical trial 03 May 2018 Pages: 85 - 94
Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ C. WadstenA.-K. WennstigM. Sund Clinical trial Open access 05 May 2018 Pages: 95 - 101
A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study Robert ThomasMadeleine WilliamsSarah A. Smith Clinical trial Open access 07 May 2018 Pages: 103 - 110
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer Aditya BardiaAyca GucalpTiffany A. Traina Clinical trial 09 May 2018 Pages: 111 - 120
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial Cesar A. Santa-MariaAditya BardiaVered Stearns Clinical trial 11 May 2018 Pages: 121 - 129
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer G. HosteK. PunieP. Neven Clinical trial 16 May 2018 Pages: 131 - 141
Incorporation of the technologist’s opinion for arbitration of discrepant assessments among radiologists at screening mammography Angela M. P. CoolenJoost R. C. LameijerLucien E. M. Duijm Epidemiology 05 May 2018 Pages: 143 - 149
Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016) Benjamin DanielsBelinda E. KielySallie-Anne Pearson Epidemiology 07 May 2018 Pages: 151 - 159
SNP rs2071095 in LincRNA H19 is associated with breast cancer risk Ping CuiYanrui ZhaoKexin Chen Epidemiology 08 May 2018 Pages: 161 - 171
Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists Yonina R. Murciano-GoroffAnne Marie McCarthyKatrina Armstrong Epidemiology 08 May 2018 Pages: 173 - 180
Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database Jung Yoon ChoiEun Young ChoKyong Hwa Park Epidemiology 08 May 2018 Pages: 181 - 188
Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors Zhezhou HuangYan ShiQi Dai Epidemiology 09 May 2018 Pages: 189 - 198
Gene expression in triple-negative breast cancer in relation to survival Shuyang WangAlicia Beeghly-FadielXiao-ou Shu Epidemiology 10 May 2018 Pages: 199 - 207
Predictors of surveillance mammography outcomes in women with a personal history of breast cancer Kathryn P. LowryLior Z. BraunsteinJanie M. Lee Epidemiology 10 May 2018 Pages: 209 - 215
Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database Maryam ElmiArash AzinTulin D. Cil Epidemiology 14 May 2018 Pages: 217 - 223
Effect of glucocorticoid use on survival in patients with stage I–III breast cancer Ching-Hung LinPo-Ya ChuangChao-Hsiun Tang Epidemiology 14 May 2018 Pages: 225 - 234
Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer Christine Y. LuFang ZhangJ. Frank Wharam Brief Report 12 May 2018 Pages: 235 - 242
Tamoxifen-induced fatty liver disease in a Caucasian patient Karel EechouteRon H. J. MathijssenTeun van Gelder Letter to the Editor 07 May 2018 Pages: 243 - 244
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy Francesca PoggioBenedetta ConteMatteo Lambertini Letter to the Editor 09 May 2018 Pages: 245 - 246